Please login to the form below

Not currently logged in
Email:
Password:

Hetlioz

This page shows the latest Hetlioz news and features for those working in and with pharma, biotech and healthcare.

BMS' Opdivo backed as melanoma therapy in EU

BMS' Opdivo backed as melanoma therapy in EU

Vanda Pharmaceuticals got the go-ahead for Hetlioz (tasimelteon) for the treatment of non-24-hour sleep wake disorder in totally blind adults - which was approved in the US last year -

Latest news

  • FDA approves sleep disorder drug for blind people FDA approves sleep disorder drug for blind people

    Vanda Pharmaceuticals wins backing for Hetlioz to improve a person’s body clock. ... This means Vanda was able to take advantage of a number of development incentives due to the orphan-drug designation for Hetlioz.

  • FDA panel backs sleep pattern drug for blind FDA panel backs sleep pattern drug for blind

    Vanda’s Hetlioz intended to improve circadian rhythms in people who cannot see. ... A Food Drug and Administration (FDA) advisory committee voted unanimously to recommend approval of Vanda Pharmaceuticals' Hetlioz (tasimelteon) for non-24-hour disorder

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Fendix is the only NHS digital media network and it provides organisations, such as pharma, with unrivalled digital access to...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics